<DOC>
	<DOCNO>NCT00195650</DOCNO>
	<brief_summary>The purpose study ass long-term safety clinical efficacy follow repeat administration adalimumab patient rheumatoid arthritis .</brief_summary>
	<brief_title>Long Term Open Label Continuation Study</brief_title>
	<detailed_description>Study DE020 multicenter , open-label continuation study patient rheumatoid arthritis participate prior Phase 1 , 2 , 3 adalimumab study United States Canada , favorable safety efficacy profile treat adalimumab , meet eligibility criterion continuation study . Participants receive subcutaneous injection adalimumab every week ( eow ) monthly base adalimumab regimen receive prior study ( i.e. , participant receive monthly dose prior study begin continuation study monthly dosing ; participant begin adalimumab dose eow interval ) . Participants maintain American College Rheumatology 50 % ( ACR50 ) response 2 consecutive visit could dose interval lengthen monthly dosing schedule . Safety efficacy data collect 520 week ( 10 year ) . Both safety efficacy data analyze use participant receive least 1 dose open-label adalimumab 10-year continuation study DE020 ( Full Analysis Set , n=846 ) . Three patient enter continuation study never dose excluded analysis .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion Criteria Participant prior D2E7 ( adalimumab ) study Participant age 18 old good health ( Investigator discretion ) recent stable medical history . Exclusion Criteria Participant consider investigator , reason , unsuitable candidate study Participant female subject pregnant breastfeeding consider become pregnant Participant ongoing chronic active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>